At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Tozorakimab (drug), Placebo (drug)
- How long the study runs
- Study runs about 59 months (dates as stated)
- About the drug or intervention
- Tozorakimab — drug: Single IV dose of tozorakimab on Day 1. · Placebo — drug: Single IV dose of matching placebo on Day 1.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 3,527
- Started
- 2022-12-13
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for viral lung infection and acute respiratory failure
- • Phase3 - 3,527 participants
- • The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with viral lung infection and acute respiratory failure
Where?
- • Bristol - Research Site
- • Dundee - Research Site
- • Glasgow - Research Site
- • Glasgow - Research Site
- • +11 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Adult participants ≥ 18 years old at the time of signing the agreement to take part form.
- ✓Patients hospitalised with viral lung infection.
- ✓Hypoxaemia requiring treatment with supplemental O2.
- ✓Hypoxaemia is defined as:
- ✓SpO2 ≤ 90% OR
Who cannot take part
- ✗Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology.
- ✗Ongoing IMV/ECMO at randomisation.
See the full criteria
Where Is This Study? (15 UK sites)
Research Site
Bristol BS105NB, United Kingdom
Research Site
Dundee DD1 9SY, United Kingdom
Research Site
Glasgow G4 0SF, United Kingdom
Research Site
Glasgow G51 4TF, United Kingdom
Research Site
Hampshire SO16 6YD, United Kingdom
Research Site
Huddersfield HD3 3EA, United Kingdom
Research Site
Leeds LS9 7TF, United Kingdom
Research Site
Leicester LE3 9QP, United Kingdom
Research Site
London W1T 7HA, United Kingdom
Research Site
London W2 1NY, United Kingdom
Research Site
London W6 8RF, United Kingdom
Research Site
Oxford OX3 9DU, United Kingdom
Research Site
Prescot L35 5DR, United Kingdom
Research Site
Tyne and Wear NE29 8NH, United Kingdom
Research Site
Wythenshawe M23 9LT, United Kingdom
How to Get in Touch
AstraZeneca Clinical Study Information Center
Sponsor contactCONTACT
